SMARTS (Systematic Monitoring of Adverse events Related to TreatmentS): ThE development of a pragmatic patient-completed checklist to assess antipsychotic drug side effects

Therapeutic Advances in Psychopharmacology

Volumn 4, Issue 1, 2014, Pages 15-21

  Haddad, Peter m ^a   Fleischhacker, w Wolfgang ^b   Peuskens, Joseph ^c   Cavallaro, Roberto ^d   Lean, Michael ej ^e   Morozova, Margarita ^f   Reynolds, Gavin ^g   Azorin, Jean Michel ^h   Thomas, Pierre ⁱ   Möller, Hans Jürgen ^j  

^a GREATER MANCHESTER MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^g SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

^h HÔPITAL SAINTE MARGUERITE   (France)

ⁱ UNIV LILLE   (France)

^j UNIVERSITY OF MUNICH   (Germany)

more..

Author keywords

antipsychotics; checklist; rating scale; side effects; tolerability

Indexed keywords

EID: 84997995326     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125313510195     Document Type: Article

References (23)

1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists and North American Association for the Study of Obesity (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27: 596–601.
2. Barnes T. (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154: 672–676.
3. Barnes T. Paton C. (2012) Poster 201. Improving side effect monitoring in people prescribed antipsychotic long-acting injections: a UK quality improvement programme. Schizophr Res 136(Suppl. 1): S258.
4. Clinical Standards Board for Scotland (2001) Clinical standards: schizophrenia. Available at: http://www.healthcareimprovementscotland.org/default.aspx?page=13628 (accessed June 2013).
5. Day J. Wood G. Dewey M. Bentall R. (1995) A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. Br J Psychiatry 166: 650–653.
6. De Hert M. Dekker J. Wood D. Kahl K. Holt R. Möller H. (2009) Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 24: 412–424.
7. Fakhoury W. Wright D. Wallace M. (2001) Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline. Int Clin Psychopharmacol 16: 153–162.
8. Fleischhacker W. (2009) Tolerability of antipsychotics: recent controversies and future management. J Clin Psychiatry 70: e06.
9. Guy W. (1976) ECDEU assessment manual for psychopharmacology, revised edn. Available at: http://archive.org/stream/ecdeuassessmentm1933guyw#page/4/mode/2up (accessed June 2013).
10. Haddad P. Sharma S. (2007) Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 21: 911–936.
11. Hamer S. Haddad P. (2007) Adverse effects of antipsychotics as outcome measures. Br J Psychiatry 50(Suppl.): s64–s70.
12. Lacro J. Dunn L. Dolder C. Leckband S. Jeste D. (2002) Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 63: 892–909.
13. Lambert M. Conus P. Eide P. Mass R. Karow A. Moritz S. et al. (2004) Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur Psychiatry 19: 415–422.
14. Lean M. Pajonk F. (2003) Patients on atypical antipsychotic drugs: another high risk group for the 2 diabetes. Diabetes Care 26: 1597–1605.
15. Levine J. Schooler N. (1986) SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull 22: 343–381.
16. Lindström E. Lewander T. Malm U. Malt U. Lublin H. Ahlfors U. (2001) Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat). Nord J Psychiatry 55(Suppl. 44): 5–69.
17. Lingjaerde O. Ahlfors U.G. Bech P. Dencker S. Elgen K. (1987) The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 76(Suppl. s334): 1–100.
18. National Institute for Health and Care Excellence (2009) Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (CG82) (update). Available at: http://guidance.nice.org.uk/CG82/Guidance (accessed June 2013).
19. Simpson G. Angus J. (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212: 11–19.
20. Voruganti L. Awad A. (2004) Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology 171: 121–132.
21. Waddell L. Taylor M. (2008) A new self-rating scale for detecting atypical or second-generation antipsychotic side effects. J Psychopharmacol 22: 238–243.
22. Weiden P. Buckley P. (2007) Reducing the burden of side effects during long-term antipsychotic therapy: the role of ‘switching’ medications. J Clin Psychiatry 68(Suppl. 6): 14–23.
23. Wong M. Chen E. Lui S. Tso S. (2011) Medication adherence and subjective weight perception in patients with first-episode psychotic disorder. Clin Schizophr Relat Psychoses 5: 135–141.